Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Thalidomide Combined with Chemotherapy for Liver Metastases from Gastric Cancer
NCT05198856Phase 2Unknown
- Sponsor
- Qilu Hospital of Shandong University
- Start
- Mar 2022
- Primary completion
- Mar 2024
- Modality
- Small Molecules
01
Overview
Phase 2, open-label, single-arm trial of thalidomide in gastric cancer (GC), sponsored by Qilu Hospital of Shandong University. Primary endpoint: Progression-Free Survival at 18 months. Status: unknown.
02
Drugs
thalidomide
03
Conditions
gastric cancer (GC)
Beyond the preview
Go deeper on NCT05198856.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05198856.